Study of CBX-250 for advanced myeloid leukemias
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer called AML, high-risk MDS, or CMML that has come back or not responded to treatment.
- You must have a specific genetic marker called HLA-A*02:01 (your doctor can test for this).
- Your white blood cell count must be below 25,000 per microliter at the start of the study.
- You need to be generally active and able to take care of yourself (ECOG 0-1 or Karnofsky/Lansky 70 or higher).
- You must wait at least 60 days after a stem cell transplant, and other cancer treatments must be stopped for a period before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial tests a new drug called AMX-883 for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. It studies the drug alone and combined with another medicine to see if it is safe and effective.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
Hear when a new High Risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.